Novel ADC Offers Hope in Heavily Pretreated NSCLC Novel ADC Offers Hope in Heavily Pretreated NSCLC

Patients with EGFR-mutated NSCLC who have progressed after multiple lines of therapy may have meaningful and durable responses to a novel antibody-drug conjugate HER3-DXd, new phase 2 data suggest.Medscape Medical News
Source: Medscape Pathology Headlines - Category: Pathology Tags: Hematology-Oncology News Source Type: news